Evidence map›Paper›PMID 36052883›Full record

Trial reportCancer science2022

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.

Masaki Ri, Kenshi Suzuki, Tadao Ishida, Junya Kuroda, Taku Tsukamoto, Takanori Teshima, Hideki Goto, Carolyn C Jackson, Huabin Sun, Lida Pacaud and 6 more

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 5 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Masaki RiDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0002-9617-486X
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3219-3292
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0001-6130-1550
Taku TsukamotoDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takanori TeshimaDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Hideki GotoDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Carolyn C JacksonJanssen Research & Development, LLC; Bridgewater, New Jersey, USA.
Huabin SunJanssen Research & Development, LLC; Bridgewater, New Jersey, USA.
Lida PacaudLegend Biotech, Piscataway, New Jersey, USA.
Ei FujikawaJanssen Pharmaceutical KK, Tokyo, Japan.
Tzu-Min YehJanssen Research & Development, LLC; Bridgewater, New Jersey, USA.
Tomoyoshi HatayamaJanssen Pharmaceutical KK, Tokyo, Japan.
Kensuke AidaJanssen Pharmaceutical KK, Tokyo, Japan.
Yoshihiro SunagawaJanssen Pharmaceutical KK, Tokyo, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
Janssen (Belgium) · BEHokkaido University Hospital · JPJapanese Red Cross Medical Center · JPKyoto Prefectural University of Medicine · JPNagoya City University Hospital · JP490 BioTech (United States) · US

Funding

Janssen Research & Development, LLCLegend Biotech USA, Inc
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen have shown positive responses in patients with multiple myeloma (MM). The phase 2 portion of the CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) included a cohort of Japanese patients with relapsed/refractory MM. Following a conditioning regimen of cyclophosphamide (300 mg/m

Indexed as

Multiple MyelomaB-Cell Maturation AntigenCyclophosphamideEast Asian PeopleHumansImmunotherapy, AdoptiveB-Cell Maturation AntigenCyclophosphamideB-cell maturation antigenBCMACAR-Timmunotherapymultiple myeloma

Identifiers

PMID36052883
PMCPMC9746030
OpenAlexW4294243332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.